We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Launches Largest DNA Multiplex Reference Standard for Oncology
Product News

Horizon Launches Largest DNA Multiplex Reference Standard for Oncology

Horizon Launches Largest DNA Multiplex Reference Standard for Oncology
Product News

Horizon Launches Largest DNA Multiplex Reference Standard for Oncology

Image Credit: Horizon Discovery

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Horizon Launches Largest DNA Multiplex Reference Standard for Oncology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery has announced the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard to support the validation of Next Generation Sequencing (NGS) assays.


OncoSpan, the world’s largest multiplexed oncology control, featuring 385 variants across 152 key cancer genes, has been specially designed using bioinformatics and droplet digital PCR, to help drive faster, easier, and more complete validation of oncology gene panels and exome sequencing assays. Horizon’s expert team has extensively characterized the background genome of OncoSpan using high coverage exome sequencing, which is provided to customers as batch-specific exome sequence data.


Horizon is, for the first time, also offering an online companion NGS QC solution called OncoMatic, developed in partnership with Euformatics to support the large amount of data generated through OncoSpan.  Access to OncoMatic will be provided free-of-charge to all OncoSpan customers. The platform enables customers to upload OncoSpan NGS data after sequencing, automatically assessing the called variants, reporting on variant frequency data, and tracking several different quality metrics per sample.  


The combination of OncoSpan and OncoMatic thereby provide access to the most accurate Reference Standard truth set for use during the establishment and validation of critical NGS bioinformatics pipelines, saving costs and helping to maintain compliance with standards such as those set by the College of American Pathology (CAP) and EuroGentest.


“Horizon has an established leadership position in the development of genetically defined reference standard materials, drawing on our distinctive ability to drive innovation, both internally and industry-wide,” commented Dr. Darrin M Disley, CEO of Horizon Discovery Group plc: “The development of large-scale, commutable Reference Standards for oncology, such as OncoSpan, along with the companion QC tool OncoMatic, will ultimately benefit patients through further enabling the development of personalized therapy solutions. Euformatics has proven to be the ideal partner for this project, and we look forward to collaborating with them on similar ventures in the future.” 

Advertisement